Dr. Jang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8081 Innovation Park Dr
Fairfax, VA 22031Phone+1 571-472-4724Fax+1 571-472-0241
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2007 - 2010
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2004 - 2007
Seoul National University College of MedicineClass of 2001
Certifications & Licensure
VA State Medical License 2014 - 2026
DC State Medical License 2010 - 2018
MD State Medical License 2011 - 2018
MN State Medical License 2009 - 2011
PA State Medical License 2004 - 2007- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Publications & Presentations
PubMed
- 22 citationsComplete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive TherapyMasood Sadaat, Sekwon Jang
Journal of Oncology Practice. 2017-12-19 - 24 citationsFive-year survival in patients with nodular and superficial spreading melanomas in the US population.Blair S. Allais, Meghan Beatson, Hongkun Wang, Shandiz Shahbazi, Lana Bijelic
Journal of the American Academy of Dermatology. 2021-04-01 - 223 citationsTumor Regression and Allograft Rejection after Administration of Anti–PD-1Evan J. Lipson, Serena M. Bagnasco, Jack Moore, Sekwon Jang, Manisha J. Patel
The New England Journal of Medicine. 2016-03-02
Press Mentions
Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage MelanomaJune 16th, 2020
Personalis, Inc. To Present New Data at the Society for Immunotherapy of Cancer’s (SITC) 33November 9th, 2011
Other Languages
- Korean
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
